昭衍新药 港股通 空最新增减持 (2026-01-28) 官网 ( 06127.hk) | 74.44 | 2.05 | 0.13% | 上市时间2021-02-26股价24.32港币涨跌幅4.38%成交金额1.11亿港币换手率0.62%市值182.24亿港币H股市值28.94亿港币总股本7.49亿H股本1.19亿每手股数100上市至今年化投资收益率-12.84%港股通持仓占H股比例62.36% (17.38亿港币2026-01-28) 累计做空占H股比例6.02% (1.84亿港币2026-01-23) | |||
| 所属三级行业生物技术 (恒生) | 市盈率 | 66.68 | 市净率 | 5.06 | 股息率 | 0.31% | 恒生:医疗保健业药品及生物科技生物技术 |
| 所属指数指数纳入纳出 | |||||||
| 同股同权 | 查看历史折扣 | ||||||
| 备注 (5): | 双击编辑备注 |
昭衍新药(06127) - 历史董事名单
| # | 姓名 | 职衔 | 职位 | 委任日期 | 辞任日期 |
|---|---|---|---|---|---|
| 1 | 張帆 | Independent Non Executive Director - A/F | 2021-02-26 | -- | |
| 2 | 歐小傑 | Independent Non Executive Director | 2019-01-01 | -- | |
| 3 | 孫明成 | Independent Non Executive Director | 2019-01-01 | -- | |
| 4 | 孫雲霞 | Executive Director | 2019-01-01 | -- | |
| 5 | 姚大林 | Executive Director | 2019-01-01 | -- | |
| 6 | 翟永功 | Independent Non Executive Director | 2019-01-01 | -- | |
| 7 | 高大鵬 | Executive Director | 2013-10-01 | -- | |
| 8 | 左從林 | Executive Director | 2012-12-01 | -- | |
| 9 | 顧曉磊 | Non Executive Director | 2012-12-01 | 2023-04-27 | |
| 10 | 馮宇霞 | Executive Director | Chairman | 2007-06-01 | -- |